caa a22 4500 605491011 CHVBK 20210128100508.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0754-7 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0754-7 Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis? [Elektronische Daten] [Hee Kwak, Byung Chae, Yong Eom, Young Hong, Jae Seo, So Lee, Byung Song, Sang Jung, Ja Bae] Background: It has been reported that the BRAF V600E mutation is related to a low frequency of background Hashimoto thyroiditis (HT); however, there are not many factors known to be related to the development of HT. The aim of this study was to determine whether patients with both papillary thyroid carcinoma (PTC) and HT show aggressive features, by investigating the clinicopathological features of HT in patients with PTC. Methods: A database of patients with PTC who underwent thyroidectomy between October 2008 and August 2012 was collected and reviewed. All 2464 patients were offered a thyroidectomy, and DNA was extracted from the atypical cells in the surgical specimens for detection of the BRAF V600E mutation. Clinical and pathological characteristics were also investigated. Results: Four hundred and fifty-two of 1945 (23.2%) patients were diagnosed with HT, and of these, 119 (72.1%) had a BRAF V600E mutation. HT was not significantly associated with the BRAF V600E mutation (P<0.001) and extrathyroidal extensions (P=0.005) but was associated with a low stage (P=0.011) and female predominance (P<0.001). In a subgroup analysis for gender, HT was associated with a low probability of BRAF V600E mutations in both genders (P<0.001 for both females and males). Also, recurrence was significantly associated with HT (OR 0.297, CI 0.099-0.890, P=0.030), lymph node ratio (OR 2.545, CI 1.092-5.931, P=0.030), and BRAF V600E mutation (OR 2.075, CI 1.021-4.217, P=0.044). However, there was no relationship with clinicopathological factors or with death. Conclusions: Our results show that HT in patients with PTC is associated with a low probability of BRAF V600E mutations. Moreover, HT was correlated with some factors that were associated with less aggressive clinical features and inversely related to recurrence. Therefore, these results may be useful to predict whether PTC concurrent with HT exhibits a better prognosis than PTC alone. Japan Society of Clinical Oncology, 2014 Hashimoto thyroiditis nationallicence BRAF V600E mutation nationallicence Papillary thyroid carcinoma nationallicence Kwak Hee Department of Surgery, Korea University College of Medicine, Seoul, Republic of Korea aut Chae Byung Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut Eom Yong Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut Hong Young Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut Seo Jae Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut Lee So Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut Song Byung Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut Jung Sang Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut Bae Ja Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 463-473 1341-9625 20:3<463 2015 20 10147 https://doi.org/10.1007/s10147-014-0754-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0754-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kwak Hee Department of Surgery, Korea University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Chae Byung Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Eom Yong Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Hong Young Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Seo Jae Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Lee So Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Song Byung Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Jung Sang Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Bae Ja Department of Surgery, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 463-473 1341-9625 20:3<463 2015 20 10147